You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 10,189,897


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,189,897
Title:Protein purification
Abstract: The present invention relates to a process for the purification of an antibody fragment from a periplasmic cell extract comprising a first cation exchange chromatography step and a second anion exchange chromatography step.
Inventor(s): Spitali; Mariangela (Slough, GB), Symmons; Jonathan (Slough, GB), Whitcombe; Richard (Slough, GB), Pearce-Higgins; Mark Robert (Slough, GB)
Assignee: UCB PHARMA, S.A. (Brussels, BE)
Application Number:14/977,688
Patent Claims:1. A process for the purification of an antibody fragment comprising: a) a first chromatography step to capture the antibody fragment wherein a periplasmic cell extract containing bacterial host cell protein in an amount of about 200 .mu.g/ml to 10,000 .mu.g/ml and an antibody fragment at a concentration of at least 1.5 g/L is subjected to cation exchange chromatography and subsequently eluted to produce a first eluate containing the antibody fragment; and b) a second chromatography step wherein the first eluate is subjected to anion exchange chromatography to capture impurities and produce a flow through containing the antibody fragment.

2. The process according to claim 1, wherein the process comprises not more than two chromatography steps.

3. The process according to claim 1, wherein all chromatography steps are performed on a chromatography column.

4. The process according to claim 1, wherein the cation exchange chromatography is performed in elution mode.

5. The process according to claim 1, wherein the first cation chromatography step comprises the following steps in sequential order: a) loading the periplasmic cell extract containing the antibody fragment onto the cation exchange column, b) washing the cation exchange column with a wash buffer, and c) eluting the antibody fragment with an elution buffer.

6. The process according to claim 5, wherein the pH of the washing buffer is identical to the pH of the periplasmic cell extract containing the antibody fragment prior to first chromatography step.

7. The process according to claim 5, wherein the periplasmic cell extract containing the antibody fragment, prior to the first chromatography step, has a pH of between 4.0 to 5.0.

8. The method according to claim 5, wherein the conductivity, pH and salt concentration of the wash buffer is unchanged during the washing of the cation exchange column.

9. The process according to claim 1, wherein the first chromatography step comprises cation exchange chromatography performed at a flow rate of at least 300 cm/h.

10. The process according to claim 1, wherein the first chromatography step comprises cation exchange chromatography performed at a conductivity of not more 6 mS/cm.

11. The process according to claim 1, wherein the first chromatography step comprises cation exchange chromatography performed in a chromatography column comprising sulphonyl, sulphopropyl or carboxymethyl coupled to a resin.

12. The process according to claim 11, wherein the cation exchange chromatography column contains a resin that has a mean particle size of at least 50 .mu.m.

13. The process according to claim 1, wherein the first chromatography step comprises cation exchange chromatography on a column containing a resin that has a dynamic binding capacity for the antibody fragment of between 50 and 75 g/L resin.

14. The process according to claim 1, wherein between 5 and 100 g of antibody fragment per liter are loaded onto a cation exchange chromatography resin.

15. The process according to claim 1, wherein the second chromatography step comprises anion exchange chromatography on a resin comprising quaternary ammonium (Q), diethylaminoethyl (DEAE) or trimethylaminoethyl (TMAE).

16. The process according to claim 1, wherein the antibody fragment is a Fab, Fab' or scFv.

17. The process according to claim 16, wherein the Fab or Fab' binds specifically to VEGF-A, FcRn, OX40, glycoprotein IIb/IIIa receptor, C5, HER2/neu, TNF.alpha., IL1.beta. or CD40-L.

18. The process according to claim 17, wherein the Fab or Fab' is abciximab, ranibizumab, pexelizumab, CDP870, CDP484 or CDP7657.

19. The process according to claim 1, wherein the antibody fragment recovered from the process contains host cell protein in an amount of not more than 150 parts per million.

20. A process for the purification of an antibody fragment from periplasmic cell extract consisting essentially of: a) a first chromatography step to capture the antibody fragment wherein a periplasmic cell extract containing bacterial host cell protein in an amount of about 200 .mu.g/ml to 10,000 .mu.g/ml and an antibody fragment at a concentration of at least 1.5 g/L is subjected to cation exchange chromatography and subsequently eluted to produce a first eluate containing the antibody fragment; b) a first ultrafiltration applied to the first eluate; c) a second chromatography step wherein the purified first eluate is subjected to anion exchange chromatography to capture impurities and produce a flow through containing the antibody fragment; and d) a second ultrafiltration applied to the flow through.

Details for Patent 10,189,897

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Janssen Biotech, Inc. REOPRO abciximab Injection 103575 12/22/1994 ⤷  Try a Trial 2030-07-27
Genentech, Inc. LUCENTIS ranibizumab Injection 125156 06/30/2006 ⤷  Try a Trial 2030-07-27
Genentech, Inc. LUCENTIS ranibizumab Injection 125156 08/10/2012 ⤷  Try a Trial 2030-07-27
Genentech, Inc. LUCENTIS ranibizumab Injection 125156 10/13/2016 ⤷  Try a Trial 2030-07-27
Genentech, Inc. LUCENTIS ranibizumab Injection 125156 03/20/2018 ⤷  Try a Trial 2030-07-27
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.